Galmed Pharmaceuticals Ltd. develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH)in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus. The company also engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine.
